666 reports of this reaction
1.4% of all GALCANEZUMAB GNLM reports
#17 most reported adverse reaction
INJECTION SITE BRUISING is the #17 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 666 FDA adverse event reports linking GALCANEZUMAB GNLM to INJECTION SITE BRUISING. This represents approximately 1.4% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience injection site bruising should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE BRUISING is a less commonly reported adverse event for GALCANEZUMAB GNLM, but still significant enough to appear in the safety profile.
In addition to injection site bruising, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to injection site bruising in FDA adverse event reports:
INJECTION SITE BRUISING has been reported as an adverse event in 666 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE BRUISING accounts for approximately 1.4% of all adverse event reports for GALCANEZUMAB GNLM, making it a notable side effect.
If you experience injection site bruising while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.